Search
Trazodone
go.drugbank.com/drugs/DB00656ApprovedInvestigationalreceptor inhibitor (SNRIs) in the treatment of depression. … [T646] It was initially granted FDA approval in 1981.[L3484]
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[A32552] Disease severity is linked to the level of factor IX activity in the blood plasma, ranging from increased bleeding after injuries and surgical operations to spontaneous bleeding, hemorrhages in … from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalMutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Tropicamide
go.drugbank.com/drugs/DB00809Approved[A229958] It is also used in combination with [hydroxyamphetamine] for the same indication. … Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors.
Pegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigationalFood and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients with phenylketonuria (PKU). … Phenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United
Efinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalIt was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Vemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalAfter approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.
Candicidin
go.drugbank.com/drugs/DB01152ApprovedInvestigationalWithdrawnCandicidin is administered intravaginally in the treatment of vulvovaginal candidiasis. … Candicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans).
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approved[L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals. … The active ingredient found in drug products of lotilaner is the S-enantiomer.
Synonyms: 2-thiophenecarboxamide, 5-((5s)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl)-3-methyl-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-, 3-methyi-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-((55)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl)thiophene-2-carboxamide